Anne Barlier Selected Research

Growth Hormone-Secreting Pituitary Adenoma

6/2021	Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.
1/2016	In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.
12/2014	Ghrelin receptor (GHS-R1a) and its constitutive activity in somatotroph adenomas: a new co-targeting therapy using GHS-R1a inverse agonists and somatostatin analogs.
12/2008	Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.
9/2007	Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment.
10/2004	Lentiviral vectors efficiently transduce human gonadotroph and somatotroph adenomas in vitro. Targeted expression of transgene by pituitary hormone promoters.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anne Barlier Research Topics

Disease

36	Neoplasms (Cancer) 07/2021 - 05/2007
16	Pituitary Neoplasms (Pituitary Adenoma) 01/2020 - 10/2004
10	Paraganglioma (Paragangliomas) 05/2020 - 05/2009
8	Pheochromocytoma 05/2018 - 05/2009
7	Meningioma (Meningiomas) 01/2021 - 08/2015
7	Neuroendocrine Tumors (Neuroendocrine Tumor) 02/2020 - 04/2014
6	Growth Hormone-Secreting Pituitary Adenoma 06/2021 - 10/2004
6	Hypopituitarism (Sheehan's Syndrome) 01/2021 - 03/2004
6	Prolactinoma (Prolactinomas) 01/2019 - 05/2007
5	Adenoma (Adenomas) 01/2016 - 10/2004
3	Acromegaly 06/2021 - 12/2014
3	Primitive Neuroectodermal Tumors (PNET) 02/2020 - 10/2014
3	Combined Pituitary Hormone Deficiency 01/2019 - 09/2006
3	Neoplasm Metastasis (Metastasis) 08/2017 - 06/2012
2	Hypoxia (Hypoxemia) 01/2020 - 02/2016
2	Polyostotic Fibrous Dysplasia (McCune Albright Syndrome) 01/2019 - 10/2014
2	Polycythemia (Erythrocytosis) 05/2018 - 05/2013
2	Hyperplasia 12/2017 - 03/2016
2	Pseudohypoparathyroidism 12/2016 - 04/2015
2	Gigantism 03/2016 - 12/2014
2	Infections 01/2012 - 12/2008
2	Carcinogenesis 05/2007 - 05/2007
1	Endocrine System Diseases (Endocrine Diseases) 01/2020
1	Hypertension (High Blood Pressure) 05/2018
1	Hemangioblastoma 05/2018
1	Islet cell tumor syndrome 12/2017
1	Pituitary ACTH Hypersecretion 08/2017
1	Adrenocortical Carcinoma 12/2015
1	Uniparental Disomy 04/2015
1	Macroglossia 04/2015
1	Necrosis 01/2015
1	Hypothyroidism 01/2015

Drug/Important Bio-Agent (IBA)

15	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 07/2021 - 05/2008
12	Octreotide (Sandostatin)FDA LinkGeneric 01/2021 - 09/2007
9	ProlactinIBA 03/2016 - 12/2006
8	Somatostatin Receptors (Somatostatin Receptor)IBA 09/2017 - 12/2008
7	Transcription Factors (Transcription Factor)IBA 01/2019 - 03/2004
7	Proteins (Proteins, Gene)FDA Link 12/2017 - 05/2007
6	Dopamine (Intropin)FDA LinkGeneric 06/2021 - 05/2008
6	Succinate Dehydrogenase (Fumarate Reductase)IBA 05/2020 - 05/2009
6	Messenger RNA (mRNA)IBA 09/2017 - 09/2007
6	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2015 - 03/2005
5	Growth Hormone (Somatotropin)IBA 06/2021 - 12/2008
5	Everolimus FDA Link 01/2021 - 08/2015
5	Dopamine Agonists (Dopamine Agonist)IBA 01/2019 - 02/2006
5	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 08/2017 - 05/2009
5	Hormones (Hormone)IBA 10/2014 - 03/2004
4	Cabergoline FDA LinkGeneric 01/2019 - 02/2006
4	pasireotideIBA 08/2017 - 05/2008
4	aryl hydrocarbon receptor-interacting proteinIBA 10/2013 - 05/2007
3	Pharmaceutical PreparationsIBA 01/2021 - 12/2014
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 04/2015
2	fluorodopa F 18IBA 02/2020 - 12/2017
2	Human Growth Hormone (Saizen)FDA LinkGeneric 01/2020 - 10/2004
2	Temozolomide (Temodar)FDA LinkGeneric 01/2019 - 06/2012
2	Adenosine Monophosphate (AMP)IBA 01/2019 - 01/2013
2	NormetanephrineIBA 05/2018 - 03/2017
2	Parathyroid Hormone (Parathormone)IBA 12/2016 - 04/2015
2	Glycoproteins (Glycoprotein)IBA 06/2016 - 10/2004
2	Succinic Acid (Succinate)IBA 01/2015 - 01/2013
2	Glutamic Acid (Glutamate)FDA Link 01/2015 - 01/2013
2	Dopamine Receptors (Dopamine Receptor)IBA 12/2013 - 04/2011
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 05/2013 - 04/2011
2	TBR-760IBA 05/2012 - 05/2008
2	GlucocorticoidsIBA 12/2011 - 03/2005
1	Protein Isoforms (Isoforms)IBA 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	gallium Ga 68 dotatateIBA 02/2020
1	somatostatin receptor 2IBA 01/2020
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2020
1	Cell-Free Nucleic AcidsIBA 01/2019
1	FluorineIBA 05/2018
1	Glucose (Dextrose)FDA LinkGeneric 05/2018
1	Retinaldehyde (Retinal)IBA 05/2018
1	Myc associated factor XIBA 12/2017
1	RadiopharmaceuticalsIBA 08/2017
1	TOR Serine-Threonine KinasesIBA 06/2017
1	IronIBA 03/2017
1	SulfurIBA 03/2017
1	Parathyroid Hormone-Related ProteinIBA 12/2016
1	Immunoglobulins (Immunoglobulin)IBA 06/2016
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 06/2016
1	pegvisomant FDA LinkGeneric 01/2016
1	Insulin (Novolin)FDA Link 12/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2015
1	Cyclin D1IBA 08/2015
1	Mechanistic Target of Rapamycin Complex 1IBA 08/2015
1	Neurofibromin 2 (Merlin)IBA 08/2015
1	Thyroxine (Levothyroxine)FDA LinkGeneric 04/2015
1	CaspasesIBA 01/2015
1	Methionine (L-Methionine)FDA Link 01/2015
1	Substance PIBA 12/2014
1	Ghrelin ReceptorsIBA 12/2014
1	Chromogranin AIBA 10/2014
1	Biological ProductsIBA 10/2014

Therapy/Procedure

17	Therapeutics 06/2021 - 10/2004
4	Radiotherapy 01/2020 - 11/2010
2	Drug Therapy (Chemotherapy) 08/2015 - 06/2012
1	Aftercare (After-Treatment) 01/2020
1	Proton Therapy 01/2020